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Abstract
Background: A growing body of evidence supports the safety of the human papillomavi-
rus (HPV) vaccines. However, concerns about autonomic dysfunction syndromes and
non-specific symptoms continue to linger. These conditions are not easily captured by
traditional diagnostic classification schemes and call for innovative approaches to
the study of vaccine safety which take more general measures of all-cause morbidity
into account.
Methods: Taking advantage of the unique Danish registers, including regional registration
of absence from school, we conducted a cohort study of 14 068 adolescent Danish girls
attending 5th through 9th grade in public schools in the municipality of Copenhagen
during 1 August 2013–23 January 2018. We obtained time-varying HPV vaccination status
and demographic information from nationwide registers. Using Poisson regression
with random effects, we estimated rate ratios (RRs) of absence due to illness, comparing
HPV-vaccinated girls with unvaccinated girls with adjustment for grade, season, calendar
period, demographic factors and random effects at the individual, class and school levels.
Results: Our study included 6 206 188 school days with 213 221 days of absence from
school due to illness (absence rate, 3.4%). Comparing absence rates due to illness in
HPV-vaccinated and unvaccinated girls yielded an adjusted RR of 1.00 (95% confidence
interval [CI], 0.98–1.03).
Conclusions: Our study provides an important and novel contribution to HPV vaccine
safety. Using absence from school records, we were able to address important safety
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concerns without relying on medical diagnoses. We conclude that HPV vaccination does
not increase the risk of morbidity in any manner that manifests as absence from school
due to illness.
Key words: HPV vaccination, vaccine safety, school absence, all-cause morbidity
Introduction
Human papillomavirus (HPV) vaccines have now been in
use for more than a decade. Despite an excellent safety
record demonstrated in numerous studies,1 concerns about
adverse events in the form of autonomic dysfunction syn-
dromes continue to linger and have caused serious setbacks
in national immunization programmes in countries such as
Japan, Denmark and Ireland. Most of these concerns have
originated from case reports and sensationalist media
reporting, and have not been substantiated in observational
studies.2–5 A closer look at the spontaneous adverse event
reports have revealed that specific syndromes are rare in
contrast to non-specific symptoms such as fatigue, head-
ache, nausea and dizziness. In the US Vaccine Adverse Event
Reporting System, only one case of postural orthostatic
tachycardia syndrome (POTS) was reported per 6.5 million
doses of distributed HPV vaccine.6 In contrast, headache,
dizziness, fatigue and nausea were common among reports.
In our own evaluation of HPV vaccine adverse event reports
in Denmark, fatigue, headache and dizziness were the three
most commonly reported symptoms.7 Non-specific symp-
toms are obviously difficult to study using databases and
registers, in contrast to outcomes with straightforward
diagnostic guidelines. These difficulties call for new and
innovative approaches to measure the impact of vaccination
on all-cause morbidity, not easily captured through studies
relying on diagnostic classification systems. We took advan-
tage of the unique nationwide registers in Denmark and
conducted a pioneering study of the association between
HPV vaccination and absence from school due to illness, in
a large cohort of Danish children. We hypothesized that if
HPV vaccination is associated with increased risk of non-
specific symptoms among HPV-vaccinated girls, this would
result in more absence from school due to illness than
among their unvaccinated peers.
Methods
Study cohort and absence from school
We constructed a study cohort from a regional registration
system of school attendance records from the municipality
of Copenhagen—the capital of Denmark. This registration
covered all public schools in Copenhagen from the start of
the school year 2013/2014 (1 August 2013) to 23 January
2018, and contained daily attendance records for individ-
ual children with information on school, grade and class.
In the register, possible absence for each school day was
recorded as absence due to illness, exceptional absence or
illegal absence. We included girls in grades 5–9. Each girl
was identifiable through a unique personal ID assigned to
all people living in Denmark.8 This unique ID is used in all
other national registers and allows for individual-level
linkage of health-related information, including vaccina-
tions, and demographic information. The study was
approved by the Danish Data Protection Agency (approval
no. 19/07650). Ethical approval is not needed for register-
based research in Denmark.
HPV vaccination and demographic information
The Danish childhood vaccination programme is voluntary
and free of charge. HPV vaccination with a quadrivalent
Key Messages
• A regional Danish register of school absence due to illness has provided a unique opportunity to study human
papillomavirus (HPV) vaccine safety concerns that cannot easily be studied using traditional diagnostic codes.
• In a regional Danish cohort of 14 068 adolescent girls, HPV-vaccinated girls and unvaccinated girls had virtually
identical rates of absence from school due to illness.
• Our study provides a strong argument that HPV vaccination does not increase the risk of any forms of illness,
including illness which is not recorded in administrative registers using diagnostic classification schemes.
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vaccine (GardasilV
R
, MSD) was included in the Danish
schedule for 12-year-old girls on 1 January 2009, with
catch-up vaccination of 13–15 year old girls starting
October 2008. The bivalent vaccine (CervarixV
R
, GSK)
replaced the quadrivalent vaccine between 1 February
2016 and 31 October 2017. Since 1 November 2017, the
nonavalent vaccine (Gardasil9V
R
, MSD) has been used. We
obtained information on HPV vaccinations from the
Danish Vaccination Registry, which contains individual-
level longitudinal information on all vaccinations in the
Danish childhood vaccination programme.9
We obtained information on birth order, the mother’s
age at the time of birth and the mother’s civil status, from
the Danish Civil Registration System for each girl in the
study cohort.8
Statistical methods
In our main analysis, we analysed days of absence due to
illness during the study period according to HPV vaccina-
tion status and other study covariates (Supplementary
Materials—Description of data, available as Supplementary
data at IJE online). Vaccination was considered a time-
varying variable. To take individual-level effects and clus-
ter effects from schools and classes into account, we used
generalized linear mixed effects modelling (Supplementary
Materials—Generalized linear mixed effects models, avail-
able as Supplementary data at IJE online) in the form of
Poisson regression with random effects to estimate the
effect of vaccination on absence from school due to illness,
using rate ratios (RRs) comparing absence rates in HPV-
vaccinated and unvaccinated girls.10 Unless otherwise
specified, all vaccination effects were estimated with
adjustment (adjusted RRs) for calendar year (2013–2018
in 1-year intervals), season (January-March, April-June,
July-September, October-December), grade (5th , 6th , 7th,
8th , 9th), birth order (1, 2, 3, 4þ), age of the mother at
the time of birth (up to 19 years, 20–24, 25–29, 30–34,
35–39, 40þ years) and the civil status of the mother at
baseline (married, unmarried, divorced or dead) as fixed
effects, while handling over-dispersion through random
effects at the individual, class and school levels. Random
effects were modelled as random intercepts. Class was
considered a nested random effect inside school, whereas
the individual effect was not, due to the possibility of girls
changing schools during the study period. A class was
defined as a given class at a given school within a given
year. In secondary analyses, we estimated RRs stratified
according to: (i) calendar year of first vaccination (before
2011, 2012–2016 in 1-year intervals, 2017þ), grade at
first vaccination (before study entry, 5th , 6th , 7th , 8th ,
9th) and season at first vaccination (January-March,
April-June, July-September, October-December); and (ii)
time since the most recent HPV vaccination (0–13 days,
14–90 days, 91–365 days, 366þ days).
To evaluate the association between vaccination and
longer periods of absence due to illness, we analysed: (i)
days of absence due to illness in excess of a certain number
of days; and (ii) periods of absence due to illness of at least
a given length (Supplementary Materials—Description
of data). Similar to the main analysis of single days of
absence, we used Poisson regression with random effects to
estimate adjusted RRs comparing rates of excess days or
rates of periods in HPV-vaccinated and unvaccinated girls.
We considered periods of length 1 to 21 days (in 1-day
increments) and days in excess of 0 to 20 days (in 1-day
increments). These datasets become increasingly sparse
with increasing period lengths, resulting in increasing levels
of over-dispersion and convergence issues. We evaluated
the robustness of the Poisson regression with random
effects by using perturbation analysis (Supplementary
Materials—Robustness, available as Supplementary data
at IJE online).11
We conducted a sensitivity analysis of absence due to
illness, where we only included girls who were HPV-
unvaccinated at entry into the study: a ‘new vaccinee’
design. We further conducted an analysis of all days of
absence in contrast to only absence due to illness, and
repeated the main analysis of absence due to illness using
negative binomial regression with random effects. Finally,
we modelled the impact of misclassification of truancy as
absence due to illness, and the sensitivity of our approach
when associations between HPV vaccination and cause-
specific morbidity were simulated in our data (Supplementary
Materials—Modelling the impact of bias, available as
Supplementary data at IJE online).
Data management and statistical analyses were con-
ducted using R version 3.5.1 [R Core Team (2017)].
Mixed effects modelling was conducted using the lme4
package. Perturbation analysis was conducted using the
perturb package.
Results
The Copenhagen municipality registration system of
school attendance comprised attendance records for
6 786 767 school days in the 1 August 2013–23 January
2018 period for 15 809 girls attending 5th-9th grade. We
excluded 143 girls with unknown date of birth or invalid
ID, 1261 girls who were not born in Denmark and 337
girls attending schools with less than 10 000 registered
school days in the study period (see study flowchart in
Figure 1). This resulted in 14 068 girls in the final study
cohort with 6 206 188 school days during follow-up (mean
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number of school days of follow-up, 441.2 days). The
study cohort comprised records from 60 unique schools
and 3542 unique classes. There were: 480 934 days of ab-
sence in the study (absence rate, 7.7%); 113 830 days of
exceptional absence (1.8%); 153 883 days of illegal ab-
sence (2.5%); and 213 221 days of absence due to illness
(3.4%). Absence due to illness increased slightly with in-
creasing grade (absence rate of 3.2% in 5th grade com-
pared with 3.5% in 9th grade), was fairly consistent across
calendar years except for 2018 (3.2%) and was highest in
the January-March period (4.3%) (Table 1). Girls with
older mothers (40þ years of age, 4.1%), without older sib-
lings (3.5%) and with unmarried, divorced or dead moth-
ers (3.9%) had the highest absence rates (Table 1). The
girls in the study spent 3 432 675 days as HPV-vaccinated
and 2 773 513 as unvaccinated with similar absence rates
in the two periods (3.4% and 3.5% for vaccinated and
unvaccinated girls, respectively)(Table 1).
Comparing absence rates due to illness in HPV-
vaccinated and unvaccinated girls yielded an adjusted RR
of 1.00 [95% confidence interval (CI), 0.98–1.03]
(Table 2). Tests of homogeneity for the stratifying
variables time since last vaccination, grade at first
vaccination, year of first vaccination and season at
first vaccination were all highly significant (p 0.001,
Table 2). However, this primarily reflected the study’s
high statistical power, and none of the few significantly
increased estimates were more than 5% increased
(Table 2).
The majority of absence periods in our study were of
short duration. Among 213 221 days of absence in the
study, only 9311 days (4.4%) occurred after 1 week of ab-
sence (5 school days) (Figure 2). Similarly, among 131 777
periods of any length, only 1742 (1.3%) were longer than
1 week (Figure 2). HPV vaccination was not associated
with increased rates of any absence periods; the adjusted
RR for periods of more than 1 week was 0.75 (95% CI,
0.64–0.88) and 0.73 (95% CI, 0.51–1.04) for periods of
more than 2 weeks (Figure 2). When analysing excess days
of absence, the adjusted RR for days occurring after 1 week
of absence was 1.02 (95% CI, 0.86–1.21) (Figure 2). The
model for excess days after 2 weeks of absence did not con-
verge (see Supplementary Materials—Robustness, for a
discussion of convergence issues in the analyses of excess
Figure 1 Study flowchart
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days); the adjusted RR for excess days after 11 days was
1.39 (95% CI, 0.96–2.02).
Only including girls who were HPV-unvaccinated at
entry into the study (n¼ 9412), yielded an adjusted RR of
1.00 (95% CI, 0.98–1.02). Comparing absence rates due
to all causes yielded an adjusted RR of 0.98 (95% CI,
0.96–0.99). Using Poisson regression with neither fixed
nor random effects yielded a crude RR of 0.96 (95% CI,
0.95–0.96). The negative binomial regression with random
effects yielded an RR of 0.97 (95% CI, 0.95–1.00).
Modelling the impact of non-differential misclassifica-
tion of 5%, 10% and 20% of all single days of absence in
the study yielded RRs of 1.00 (95% CI, 0.98–1.03), 1.01
(95% CI, 0.98–1.03) and 1.00 (95% CI, 0.98–1.03),
respectively (Supplementary Materials—Modelling the im-
pact of bias). When simulating cause-specific morbidity,
we observed that cause-specific morbidity base rates as low
as 0.5% (corresponding to an average of a little less than 1
day of absence due to that particular illness per year per
girl), would result in statistically significant all-cause
morbidity RRs for even modest associations between HPV
vaccination and cause-specific morbidity. Even rarer
illnesses would also result in significant all-cause morbidity
RRs if the association with HPV vaccination was
Table 1 Descriptive characteristics of 14 068 girls attending 5th-9th grade in public schools (Copenhagen, Denmark) during
1 August 2013–23 January 2018
Characteristic Number of girls Human papillomavirus
vaccinated school days










Total 14 068 34.3 (3.4%) 27.7 (3.5%) 62.1 (3.4%)
Grade
5th 7964 0.6 (3.0%) 13.4 (3.2%) 13.9 (3.2%)
6th 7396 5.2 (3.1%) 7.7 (3.4%) 12.9 (3.3%)
7th 7135 8.7 (3.3%) 3.7 (4.2%) 12.5 (3.6%)
8th 6782 10.0 (3.5%) 1.9 (4.1%) 11.8 (3.6%)
9th 6189 9.8 (3.4%) 1.1 (4.5%) 10.9 (3.5%)
Calendar year
2013 6766 3.8 (3.3%) 2.2 (3.4%) 6.0 (3.4%)
2014 8450 8.8 (3.3%) 4.6 (3.4%) 13.4 (3.4%)
2015 8570 8.1 (3.4%) 5.4 (3.5%) 13.6 (3.4%)
2016 8743 6.9 (3.3%) 7.2 (3.6%) 14.1 (3.5%)
2017 8919 6.3 (3.5%) 7.8 (3.6%) 14.1 (3.5%)
2018 7259 0.4 (3.2%) 0.5 (3.1%) 0.9 (3.2%)
Season
January-March 13 823 9.3 (4.3%) 6.9 (4.4%) 16.2 (4.3%)
April-June 11 925 9.0 (2.5%) 5.5 (2.9%) 14.4 (2.7%)
July-September 13 869 6.5 (2.9%) 6.7 (2.8%) 13.2 (2.9%)
October-December 13 870 9.6 (3.5%) 8.7 (3.7%) 18.2 (3.6%)
Mother’s age at birth
up to 19 years 228 0.5 (2.7%) 0.4 (3.1%) 0.9 (2.8%)
20-24 1775 4.8 (3.2%) 3.1 (3.7%) 7.9 (3.4%)
25-29 4427 11.4 (3.4%) 8.7 (3.4%) 20.1 (3.4%)
30-34 4935 11.5 (3.3%) 10.0 (3.5%) 21.4 (3.4%)
35-39 2246 5.2 (3.6%) 4.6 (3.6%) 9.8 (3.6%)
40 years þ 457 0.9 (3.6%) 1.0 (4.4%) 1.9 (4.1%)
Birth order
1 6821 16.0 (3.4%) 13.8 (3.5%) 29.8 (3.5%)
2 4677 11.7 (3.5%) 9.0 (3.6%) 20.8 (3.5%)
3 1648 4.1 (3.0%) 3.1 (3.4%) 7.3 (3.2%)
4þ 922 2.4 (3.0%) 1.8 (3.3%) 4.2 (3.2%)
Mother’s civil status
Married 7704 19.0 (2.9%) 15.0 (3.2%) 34.1 (3.0%)
Unmarried, divorced or dead 6364 15.3 (3.9%) 12.7 (4.0%) 28.0 (3.9%)
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sufficiently strong (Supplementary Materials—Modelling
the impact of bias).
Discussion
We found no support for the hypothesis of HPV vaccina-
tion increasing the risk of all-cause morbidity measured as
days of absence from school due to illness. This finding
was consistent in periods following vaccination, was
independent of when vaccination was initiated (grade,
calendar year and season) and extended to longer periods
of absence.
Studies evaluating the association between HPV vacci-
nation and all-cause morbidity are rare. However, a large
body of evidence supporting the safety of HPV vaccination
with respect to specific adverse events does exist. In a re-
view of 23 HPV vaccine trials evaluating safety, no in-
creased risk of serious adverse events was reported, RR
0.98 (95% CI, 0.92–1.05).12 A number of post-licensure
safety evaluations have evaluated a wide range of well-
defined clinical outcomes such as autoimmune diseases,
neurological conditions and venous thromboembolisms
with reassuring results.5,13,14 Similarly, no well-controlled
study has linked HPV vaccination and autonomic dysfunc-
tion syndromes in the form of POTS, complex regional
pain syndrome or chronic fatigue syndrome.2–6
Infectious diseases are common in childhood and likely
a major source of absence from school. Among 598 553
Danish children born in Denmark 1987–97, 6.8% had an
infectious disease hospital contact from 10 years of age and
Table 2 Rate ratios (RRs) of absence from school due to illness according to human papillomavirus (HPV) vaccination status
among 14 068 girls attending 5th-9th grade in public schools (Copenhagen, Denmark) during 1 August 2013–23 January 2018
HPV vaccination status Number of days absent
due to illness (school days
of follow-up [100 000 days])
RR (95% CI)a P-valueb
Unvaccinated 97 638 (27.7) 1 (reference) –
Vaccinated 115 583 (34.3) 1.00 (0.98-1.03) 0.71
Time since last vaccination:c <0.001
0-13 days 2321 (0.7) 1.01 (0.96-1.05)
14-90 days 11 553 (3.6) 1.03 (1.00-1.05)
91-365 days 27 431 (8.5) 0.98 (0.96-1.00)
366þ days 74 278 (21.5) 1.02 (0.99-1.05)
Grade at first vaccination:c <0.001
Before study entry 65 916 (19.0) 0.93 (0.88-0.98)
5th grade 13 436 (4.2) 1.04 (1.00-1.09)
6th grade 30 522 (9.5) 1.00 (0.98-1.03)
7th grade 4371 (1.3) 1.03 (0.98-1.08)
8th grade 1194 (0.4) 0.97 (0.90-1.05)
9th grade 144 (0.1) 0.68 (0.55-0.83)
Year of first vaccination:c <0.001
2010 and before 5295 (1.7) 0.76 (0.67-0.85)
2011 16 139 (4.5) 0.81 (0.74-0.89)
2012 23 845 (7.0) 0.85 (0.79-0.91)
2013 26 423 (7.9) 0.95 (0.90-1.00)
2014 22 393 (6.5) 1.03 (0.99-1.07)
2015 11 260 (3.5) 1.01 (0.97-1.05)
2016 5622 (1.8) 1.01 (0.97-1.05)
2017 and after 4606 (1.5) 1.02 (0.98-1.06)
Season at first vaccinationc 0.001
January-March 26 267 (8.2) 0.97 (0.94-1.00)
April-June 34 166 (9.9) 1.04 (1.00-1.07)
July-September 27 323 (8.1) 0.98 (0.95-1.01)
October-December 27 827 (8.2) 1.03 (0.99-1.06)
aAdjusted for calendar year (2013-18 in 1-year intervals), season (January-March, April–June, July-September, October-December), grade (5th, 6th, 7th, 8th,
9th), birth order (1, 2, 3, 4þ), age of the mother at the time of birth (up to 19, 20–24, 25–29, 30–34, 35–39, 40þ years), the civil status of the mother at baseline
(married, unmarried, divorced or dead) and random effects at the individual, class and school levels.
bTest for homogeneity.
cReference category is ‘Unvaccinated’.
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until completion of the 9th grade, and 27.8% had three or
more prescriptions for anti-infective agents.15 Another
major source of absence is non-specific symptoms related
to general health well-being and mental well-being, which
are particularly common in adolescent girls according to
Health Behaviour in School-aged Children—a World
Health Organization Collaborative Cross-national
Study.16 In the most recent Danish report from 2018, 1827
girls participated. Among 13-year-old girls, only 24%
considered themselves to be in ‘really good health’;
37% reported weekly headaches; 20% stomach aches;
27% back pain; 24% dizziness; 36% episodes of feeling
Figure 2 (A) Rate ratios (y-axis) (with 95% confidence interval bars) of periods of absence from school due to illness according to human papillomavi-
rus vaccination status among 14 068 Danish girls attending 5th-9th grade during 1 August 2013–23 January 2018. Periods (x-axis) defined as at least x
consecutive days; that is, x¼5 refers to all periods spanning 5 or more days of consecutive absence due to illness. Numbers represent the total num-
ber of periods in the analysis. (B) Rate ratios (y-axis) (with 95% confidence interval bars) of days of absence from school due to illness according to
human papillomavirus vaccination status among 14 068 Danish girls attending 5th-9th grade during 1 August 2013–23 January 2018. Days (x-axis) de-
fined as all days in excess of x days in a period; that is, x¼ 5 refers to the number of days in excess of 5 days in periods spanning 5 or more days.
Numbers represent the total number of days in the analysis. Missing estimates correspond to regression models which did not converge (see
Supplementary Materials for further details, available as Supplementary data at IJE online)
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sad; 48% episodes of irritability; 42% episodes of nervous-
ness; and 45% episodes of sleeping difficulty.17 Any evalu-
ation of vaccine safety concerns relying on self-reports of
such highly prevalent non-specific symptoms would have
to consider the possibility that some vaccinees may have
inappropriately attributed their symptoms to vaccination.
To the extent such symptoms result in absence from
school, our study effectively eliminated this potential
source of reporting bias.
Our study has a number of limitations. We cannot
verify the validity of absence registered as due to illness.
However, classification of truancy as illness is unlikely to
be associated with HPV vaccination status and will result
in non-differential misclassification. Furthermore, any
truancy will most likely occur as single days of absence or
very short periods of absence. We observed no consistently
increased risks for longer periods, and modelling realistic
levels of non-differential misclassification of single days
revealed no material impact. Since our study only com-
prises school days, we have no information on illness
during weekends and school holidays. Other than a slight
loss in statistical power, this will primarily result in under-
reporting of illness period lengths and excess days of ill-
ness. Time-dependent healthy vaccinee bias, whereby sick
girls avoid or postpone vaccination, can bias results
towards a protective effect of vaccination especially in the
immediate periods following vaccination. However, there
was no protective effect of vaccination on absence in the
first 2 weeks after vaccination, suggesting that healthy vac-
cinee bias, if present, has had little influence on our results,
or conversely that healthy vaccinee bias is masking an in-
creased risk of vaccination. In any case, this is unlikely to
have any impact on our main results, since absence in the
first 2 weeks following vaccination comprises only 1.1%
of the total number of days of absence due to illness in our
study. We cannot exclude that confounding by lifestyle fac-
tors and socioeconomic factors has masked an increased
risk associated with vaccination; lifestyle-related and so-
cioeconomic factors might be associated with higher HPV
vaccine uptake and might also be associated with better
baseline health. However, our analytical approach did
include random effects at the individual, class and school
levels, which minimizes concern about confounding since
the extent to which lifestyle and socioeconomic factors
are associated with absence due to illness is addressed
indirectly by the random effects. Since this is a study of all-
cause morbidity, we cannot exclude that HPV vaccination
increases the risk of specific morbidities. However, since
our study has a very high degree of statistical power, we
can conclude that any such association could only remain
undetected in our results if sufficiently rare or for risk
increases below clinically significant levels.
Our study only included public schools. However, in
the school year 2013/14, 79% of all Danish children
attended public schools.18 The Copenhagen registration
system of absence from school records has not been vali-
dated. The overall absence rates due to all causes in our
study was 7.7%, with 3.4% being due to illness for 5th-9th
grade, which corresponds well to the national average in
the 2017/18 school year of 5.9% with 3.0% being due to
illness for 0-9th grade.19 The Danish absence rates com-
pare well with other countries; in England, an absence rate
due to illness of 2.6% was reported for the 2017/18 school
year for state-funded primary, secondary and special
schools.20
The major strength of our study is that it captures all
morbidity sufficient to cause absence from school, includ-
ing morbidity not recorded elsewhere. Further strengths in-
clude the independent ascertainment of exposure and
outcome in a prospective regional cohort and the use of a
random effects model taking morbidity patterns at the in-
dividual, class and school levels into account.
When introducing a vaccine in a new population, the
occurrence of temporal safety signals is to be expected.21,22
Subsequently, these signals must be evaluated in well-
controlled observational studies. Our study is the first to
address HPV vaccine safety signals comprising morbidity
not easily captured in traditional diagnostic classification
schemes, and our study provides an important and novel
contribution to the science of HPV vaccination safety. We
conclude that HPV vaccination does not increase the risk
of all-cause morbidity in any manner that manifests as
absence from school due to illness, and this is supported by
the high statistical power of our study, which allows us to
exclude the existence of even minute risk increases in
absence due to illness (>3% increase).
The data underlying this article comprise individual-
level information on health events and cannot be shared
publicly due to privacy concerns.
Supplementary data
Supplementary data are available at IJE online.
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